Acquired by Alfasigma S.p.A. Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. Show more

Location: | Website: www.interceptpharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$19.00

Open

$19.00

Volume

N/A

Day Range

$19.00 - $19.00

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

3.13%

Institutional Own.

81.30%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
OCALIVA® (obeticholic acid) Details
Primary biliary cholangitis, Infectious disease, COVID-19, Liver disease

Approved

Quarterly sales

Ocaliva + Bezafibrate Details
Primary biliary cholangitis, Liver disease

Phase 2

Update

INT-787 Details
Liver disease, Alcoholic hepatitis

Phase 2a

Update

Ocaliva Details
Non-alcoholic steatohepatitis , Liver disease

Failed

Discontinued

Ocaliva Details
Primary sclerosing cholangitis, Liver disease

Failed

Discontinued

Ocaliva Details
Non-alcoholic steatohepatitis , Liver disease

Failed

Discontinued